<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59337">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333526</url>
  </required_header>
  <id_info>
    <org_study_id>Syndecan-NOM</org_study_id>
    <nct_id>NCT02333526</nct_id>
  </id_info>
  <brief_title>Syndecan 1 as Biomarker for Inflammation</brief_title>
  <official_title>Soluble Syndecan 1 as Biomarker for Acute and Chronic Bowel Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helios Albert-Schweitzer-Klinik Northeim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helios Albert-Schweitzer-Klinik Northeim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from
      venous blood of patients with infectious intestinal diseases such as Clostridium
      difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or
      ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients
      with active inflammation and with disease in remission. Secondary objectives were the
      assessment of correlation of the above-mentioned factors with the CRP value. Subjects will
      be volunteers. Blood will be taken as part of the routine clinical work-up after the written
      agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay.
      In addition, the subjects are asked to answer a short questionnaire. The study is designed
      as a prospective, comparative cohort study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>Soluble serum Syndecan-1 in ng/ml</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Underlying disease</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient age</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity in Inflammatory bowel disease</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin in stool</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leucocyte blood count</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP in serum</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Colitis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood serum for soluble Syndecan 1 and CRP Leucocyte cound Blood panel Stool analysis for
      calprotectin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with inflammatoy bowel disease, infectious colitis and healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with at least 18 years of age

          -  able to give informed consent

          -  healthy volunteer or inflammatory bowel condition (inflammatory bowel disease,
             infectious colitis)

        Exclusion Criteria:

          -  not able to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Meister, PD Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Albert-Schweitzer-Klinik Northeim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Meister, PD Dr.med.</last_name>
    <phone>+495551971244</phone>
    <email>tobias.meister@helios-kliniken.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steffen Kunsch, PDDr.med.</last_name>
      <phone>+39555139-0</phone>
      <email>steffen.kunsch@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Volker Ellenrieder, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Albert-Schweitzer-Klinik Northeim</name>
      <address>
        <city>Northeim</city>
        <state>Lower Saxony</state>
        <zip>37154</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Meister, PD Dr.med.</last_name>
      <phone>+495551971244</phone>
      <email>tobiasmeister@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Martin Floer, Dr.med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>January 6, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helios Albert-Schweitzer-Klinik Northeim</investigator_affiliation>
    <investigator_full_name>Tobias Meister</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr. med. Tobias Meister</investigator_title>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>Clostidium difficile-associated colitis</keyword>
  <keyword>Syndecan-1</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Colitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
